Krystal Biotech Inc
KRYS158.230USD
+4.180+2.71%
Market hours （ET）Quotes delayed by 15 min
4.58BMarket Cap
31.20P/E TTM
More Details of Krystal Biotech Inc Company
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. It is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include VYJUVEK, KB407, KB408, KB707, KB105, KB104, KB104, and KB301. Its commercial product VYJUVEK is a non-invasive, topical, redo sable gene therapy designed to deliver two copies of theCOL7A1 gene when applied directly to DEB wounds. VYJUVEK is designed to treat DEB at the molecular level by providing the patient’s skin cells the template to make normal COL7 protein, thereby addressing the fundamental disease-causing mechanism. KB407 is developed for the treatment of Cystic Fibrosis. KB408 is developed for the treatment of Alpha-1 Antitrypsin Deficiency. KB707 is developed for the treatment of solid tumors. KB105 is developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis.
Company Info
Ticker SymbolKRYS
Company nameKrystal Biotech Inc
IPO dateSep 20, 2017
CEOMr. Krish S. Krishnan
Number of employees275
Security typeOrdinary Share
Fiscal year-endSep 20
Address2100 Wharton St Ste 701
CityPITTSBURGH
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code15203
Phone14125865830
Websitehttps://www.krystalbio.com/
Ticker SymbolKRYS
IPO dateSep 20, 2017
CEOMr. Krish S. Krishnan
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Krish S. Krishnan
Mr. Krish S. Krishnan
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.65M
-1.49%
Ms. Suma M. Krishnan
Ms. Suma M. Krishnan
President - Research and Development, Founder, Director
President - Research and Development, Founder, Director
1.58M
-1.56%
Mr. Dino A. Rossi
Mr. Dino A. Rossi
Independent Director
Independent Director
78.69K
--
Dr. Adm. Christopher (Chris) Mason, M.D., Ph.D.
Dr. Adm. Christopher (Chris) Mason, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Kirti Ganorkar
Mr. Kirti Ganorkar
Independent Director
Independent Director
--
--
Mr. Daniel S. Janney
Mr. Daniel S. Janney
Lead Independent Director
Lead Independent Director
--
--
Ms. Catherine Mazzacco
Ms. Catherine Mazzacco
Independent Director
Independent Director
--
--
Dr. Everett Rand Sutherland, M.D.
Dr. Everett Rand Sutherland, M.D.
Independent Director
Independent Director
--
--
Mr. Julian S. Gangolli
Mr. Julian S. Gangolli
Independent Director
Independent Director
--
--
Ms. Meg Dodge
Ms. Meg Dodge
Investor Relations
Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Krish S. Krishnan
Mr. Krish S. Krishnan
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.65M
-1.49%
Ms. Suma M. Krishnan
Ms. Suma M. Krishnan
President - Research and Development, Founder, Director
President - Research and Development, Founder, Director
1.58M
-1.56%
Mr. Dino A. Rossi
Mr. Dino A. Rossi
Independent Director
Independent Director
78.69K
--
Dr. Adm. Christopher (Chris) Mason, M.D., Ph.D.
Dr. Adm. Christopher (Chris) Mason, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Kirti Ganorkar
Mr. Kirti Ganorkar
Independent Director
Independent Director
--
--
Mr. Daniel S. Janney
Mr. Daniel S. Janney
Lead Independent Director
Lead Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Sep 5
Updated: Fri, Sep 5
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.95%
BlackRock Institutional Trust Company, N.A.
12.16%
The Vanguard Group, Inc.
9.74%
Avoro Capital Advisors LLC
9.19%
Krishnan (Krish S)
5.69%
Other
48.27%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.95%
BlackRock Institutional Trust Company, N.A.
12.16%
The Vanguard Group, Inc.
9.74%
Avoro Capital Advisors LLC
9.19%
Krishnan (Krish S)
5.69%
Other
48.27%
Shareholder Types
Shareholders
Proportion
Investment Advisor
52.87%
Investment Advisor/Hedge Fund
28.92%
Individual Investor
11.86%
Hedge Fund
7.29%
Research Firm
2.87%
Private Equity
2.41%
Pension Fund
1.08%
Sovereign Wealth Fund
1.01%
Venture Capital
0.59%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
590
32.63M
112.75%
-1.09M
2025Q1
597
32.73M
113.26%
-1.18M
2024Q4
555
33.11M
114.98%
-1.88M
2024Q3
532
33.56M
116.82%
-1.97M
2024Q2
492
34.00M
119.08%
+2.68M
2024Q1
457
29.99M
105.21%
-815.24K
2023Q4
418
29.64M
105.24%
-696.04K
2023Q3
406
29.89M
107.26%
-297.23K
2023Q2
399
29.15M
106.30%
+625.16K
2023Q1
372
27.33M
106.10%
-304.41K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
4.31M
14.93%
+7.02K
+0.16%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.63M
12.58%
-103.60K
-2.77%
Mar 31, 2025
The Vanguard Group, Inc.
2.82M
9.76%
-53.17K
-1.85%
Mar 31, 2025
Avoro Capital Advisors LLC
2.73M
9.45%
+102.18K
+3.89%
Mar 31, 2025
Krishnan (Krish S)
1.67M
5.79%
-25.00K
-1.47%
Mar 25, 2025
Krishnan (Suma M)
1.60M
5.55%
+25.00K
+1.58%
Mar 25, 2025
State Street Global Advisors (US)
1.23M
4.24%
-52.27K
-4.09%
Mar 31, 2025
Capital World Investors
954.47K
3.3%
+75.27K
+8.56%
Mar 31, 2025
Soleus Capital Management, L.P.
441.76K
1.53%
+83.38K
+23.27%
Mar 31, 2025
Braidwell LP
400.74K
1.39%
+200.24K
+99.87%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
